Welcome to our dedicated page for Abbvie news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie stock.
AbbVie Inc. reports pharmaceutical developments across immunology, neuroscience, oncology and Allergan Aesthetics. Recurring updates include financial results by product portfolio, clinical and real-world data for therapies such as SKYRIZI and RINVOQ, FDA regulatory submissions and response letters, and medical-conference presentations in inflammatory bowel disease and other immune-mediated conditions.
Company news also covers pipeline spending, acquired in-process research and development, manufacturing capacity for medicines in core therapeutic areas, and investor conference appearances. AbbVie’s product references commonly include SKYRIZI, RINVOQ, Botox Therapeutic, Vraylar, Ubrelvy, Qulipta, Venclexta, Imbruvica and Elahere.
AbbVie (NYSE: ABBV) announced its board declared a quarterly cash dividend of $1.73 per share. The dividend is payable August 14, 2026, to shareholders of record on July 15, 2026. Since 2013, AbbVie has raised its dividend by over 330% and is part of the S&P Dividend Aristocrats Index.
Allergan Aesthetics (NYSE: ABBV) received U.S. FDA approval for SKINVIVE by JUVÉDERM to improve neck appearance by reducing horizontal neck lines in adults over 21. This is its second indication after cheek skin smoothness.
SKINVIVE is the first and only FDA-approved hyaluronic acid injectable for neck lines, showing six-month results with optimal treatment and a mostly mild, transient safety profile.
AbbVie (NYSE: ABBV) reported nine-year Phase 3 CLL14 results for fixed-duration VENCLEXTA/VENCLYXTO (venetoclax) plus obinutuzumab in previously untreated chronic lymphocytic leukemia at EHA 2026.
The regimen showed median progression-free survival of 6.4 vs 3.2 years and median time to next treatment of 7.6 years, after one year of therapy.
Allergan Aesthetics (NYSE:ABBV) released “What Consumers Really Want”, the latest report in The Aesthetics Evolution series, profiling today’s aesthetics consumers and their expectations from personalized, end-to-end aesthetic experiences.
The report highlights themes on spending priorities, desire for natural results, value of in-depth consultations, trust in providers, and proactive approaches to aging.
AbbVie (NYSE: ABBV) is presenting extensive new data at EHA 2026 across multiple blood cancers, including MM, FL, CLL, DLBCL, AML, AL and BPDCN.
Highlights include 21 oral and poster presentations on epcoritamab, venetoclax, investigational etentamig (ABBV-383) and pivekimab sunirine-pvzy, covering efficacy, safety, biomarkers and real‑world use.
AbbVie (NYSE:ABBV) will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. Company management will join a fireside chat at 9:40 a.m. Central time.
A live audio webcast and later archived replay will be available on AbbVie's investor relations website.
AbbVie (NYSE: ABBV) received European Commission authorization for an expanded VENCLYXTO (venetoclax) label in previously untreated adult chronic lymphocytic leukemia (CLL). New all-oral, fixed-duration combinations with acalabrutinib (with or without obinutuzumab) and ibrutinib are now included.
The decision, supported by Phase 3 AMPLIFY and GLOW and Phase 2 CAPTIVATE data, applies in all EU Member States plus Iceland, Norway and Liechtenstein, and may offer patients treatment-free intervals and chemotherapy-free first-line options.
AbbVie (NYSE: ABBV) received U.S. FDA approval for DECNUPAZ (pivekimab sunirine-pvzy) to treat adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an ultra-rare and aggressive blood cancer with limited options.
The approval is based on the Phase 1/2 CADENZA trial, where newly diagnosed BPDCN patients (n=33) had a 69.7% composite complete response with 9.7‑month median duration; relapsed/refractory patients (n=51) showed a 15.7% composite complete response with 9.2‑month median duration. DECNUPAZ is the first and only CD123‑targeting antibody‑drug conjugate that can be initiated in an outpatient setting and is AbbVie’s first ADC approved for blood cancer. Common adverse reactions (≥20%) included edema, fatigue, musculoskeletal pain, hemorrhage, infusion‑related reactions, nausea, and diarrhea, and the drug carries a boxed warning for hepatotoxicity, including hepatic veno‑occlusive disease.
AbbVie (NYSE: ABBV) announced a positive CHMP opinion recommending approval of MAVIRET (glecaprevir/pibrentasvir) for treating acute hepatitis C in adults and children ≥3 years in the EU. The opinion is based on Phase 3 M20-350 data showing a 96% cure rate (SVR12) over eight weeks, with a safety profile generally consistent with prior experience. A final European Commission decision is expected in Q3 2026, which would expand MAVIRET’s indication to both acute and chronic HCV.
AbbVie (NYSE: ABBV) will present extensive oncology pipeline data at the ASCO 2026 Annual Meeting, covering solid tumors and blood cancers.
Highlights include Phase 1 Top1i ADC results in mCRPC, SCLC, PROC and HNSCC, and Phase 1b T‑cell engager data in relapsed/refractory multiple myeloma showing notable objective response rates and manageable safety profiles.